Lung Biopsy Systems Market Size & Share, by Product Type (Core Needle, Fine Needle Aspiration, Surgical Biopsy Devices); Procedure Type (Transbronchial, Thoracoscopic, Open Biopsy); End-user (Cancer Research Centers, Specialty Clinics, Hospitals) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4191
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Lung Biopsy Systems Market size is slated to cross USD 16 Billion by the end of 2035, witnessing around 15% CAGR during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of lung biopsy systems was USD 3 Billion. The reason behind the growth is impelled by a higher prevalence of lung cancer across the globe. As a result, there is a greater need for timely diagnosis which necessitates the use of a lung biopsy system. By extracting samples of lung tissue that may be utilized for molecular testing, a lung biopsy is a generally acknowledged method for identifying pulmonary illnesses. A report published by World Health Organization (WHO) stated that in 2020, around 10 million people died due to lung cancer which was summed up to be 1 in 6 deaths worldwide.

The growing inclination toward minimally invasive surgeries is believed to fuel lung biopsy systems market growth. Minimally invasive surgeries come under the ongoing advancement of the medtech industry and it is performed by delivering less damage to the body with the assistance of enhanced medical imaging equipment services.

Moreover, the use of a robotic-assisted system in minimally invasive lung biopsy enables medical professionals performing the procedure to access all 18 lung regions, enabling the best lung navigation and producing more precise biopsies. This type of treatment is safe, effective, and minimally invasive, which can reduce discomfort, recovery time, and infection risk.


Lung Biopsy Systems Market
Get more information on this report: Request Free Sample PDF

Lung Biopsy Systems Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Geriatric Population– The elderly population is more prone to chronic lung diseases and the rising number of elderly populations across the globe is estimated to drive lung biopsy systems market growth. According to estimates, the number of individuals in the world who are 60 or older will increase to over 2 billion by 2050.
  • Spiking Cases of COPD to Propel the Growth of the Market - COPD, a chronic obstructive pulmonary disease, is considered an inflammatory lung disease that is responsible for the interrupted airflow from the lungs and can result in the death of the affected person. COPD requires quick medical attention and early diagnosis to be cured thoroughly.

Challenges

  • Possibility of Side Effects Such as Blood Loss and Pneumonia– In some patients, a lung biopsy will cause side effects such as blood clots or blood loss, pain, discomfort, infection, and pneumonia. These are estimated to hamper the market growth in the coming years as per the market analysis.
  • Requirement of High Initial Investment
  • Lack of Skilled Medical Professionals

Lung Biopsy Systems Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~15%

Base Year Market Size (2022)

~ USD 3 Billion

Forecast Year Market Size (2035)

~ USD 16 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Lung Biopsy Systems Segmentation

Procedure Type (Transbronchial, Thoracoscopic, Open Biopsy)

The open biopsy segment is estimated to hold 68% share of the global lung biopsy systems market in the coming years owing to the higher number of patients receiving it. Open lung biopsy is the most common type of biopsy that is performed to check for the sigh of diseases in the lungs. It is tolerably risk-free and generally regarded as the most reliable biopsy technique. Hospitals use general anesthesia to perform open lung biopsies, where during the entire operation, patients are asleep and don't feel any pain.

End-User (Cancer Research Centers, Specialty Clinics, Hospitals)

Lung biopsy systems market from the hospitals segment is set to garner a notable share in the near future owing to an increasing number of hospitals. This offers patients with better access to healthcare services which can result in a huge number of lung biopsies being performed. For instance, patients now have a new, minimally invasive lung biopsy option available from the hospital which offers the technology and medical know-how to retrieve lung biopsy tissue samples from the deepest parts of the lung, to improve the chances of lung disease diagnosis and treatment. Besides this, hospitals provide round-the-clock services to patients and are equipped with advanced medical equipment. Medical professionals who have expertise in lung biopsy systems are also easily available within hospital premises.

Our in-depth analysis of the global lung biopsy systems market includes the following segments:

     Product Type

  • Core Needle
  • Fine Needle Aspiration
  • Surgical Biopsy Devices

      Procedure Type

  • Transbronchial
  • Thoracoscopic
  • Open Biopsy

     End Use

  • Cancer Research Centers
  • Specialty Clinics
  • Hospitals

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Lung Biopsy Systems Industry- Regional Synopsis

North American Market Forecast

Lung biopsy systems market in North America is predicted to account for the largest share of 42% by the end of 2035 impelled by growing research and clinical trials to test a new approach to treatment for lung cancer. Therefore, to support these efforts the demand for lung biopsy systems is expected to rise in the region. According to statistics, in 2021, North America saw over 25% global increase in clinical drug trial initiations.

APAC Market Statistics

The Asia Pacific lung biopsy systems market is estimated to be the second largest, during the forecast timeframe led by growing air pollution in the environment owing to the rapid urbanization and industrialization in the region. For instance, the deteriorating air pollution in India is being attributed by medical professionals to a rapid increase in cases of chest and throat sickness, and many respiratory ailments. This has led to increasing demand for lung biopsy systems in the region. India, a fast-developing nation with a growing population, suffers from severe air pollution, and it is estimated that more than 25,000 people die from it every year in Delhi.

Research Nester
Lung Biopsy Systems Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Lung Biopsy Systems Market

top-features-companies
    • Argon Medical Devices, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Fujifilm Corporation
    • Cardinal Health, Inc.
    • DTR Medical Ltd
    • B. Braun Melsungen AG
    • Becton, Dickinson and Company
    • Olympus Corporation
    • Hologic Inc.
    • Medtronic Limited
    • Zimmer Biomet Holdings, Inc

In the News

  • Fujifilm Corporation announced the completion of the installation of 50,000 medical equipment called ‘#50k and Counting – Hitting the Milestone and Getting Healthier Together’ all over India. 
  • Argon Medical Devices, Inc. introduced its Two Inferior Vena Cava Filter Retrieval Kits to be sold in the United States. This retrieval kit was developed for the transdermal removal of retrievable inferior vena cava (IVC).

Author Credits:  Radhika Pawar


  • Report ID: 4191
  • Published Date: Jul 27, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Higher prevalence of lung cancer across the globe and the growing inclination toward minimally invasive surgeries are the major factors driving the growth of the market.

The market size of Lung Biopsy Systems is anticipated to attain a CAGR of 15% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Fujifilm Corporation, Cardinal Health, Inc., DTR Medical Ltd, B. Braun Melsungen AG, Becton, Dickinson and Company, Olympus Corporation, Hologic Inc., Medtronic Limited, and others.

The open biopsy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Lung Biopsy Systems Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying